Using Ibrutinib in Chronic Lymphocytic Leukemia (CLL)
2 Views
administrator
07/08/23
The panelists, William G. Wierda, MD, PhD; Richard R. Furman, MD; Shuo Ma, MD, PhD; and Alessandra Ferrajoli, MD, identify treatment objectives and adverse events associated with the use of ibrutinib in chronic lymphocytic leukemia
-
Category
Show more
Facebook Comments
No comments found